Home › Allied-Bristol Life Sciences Launches ieCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway
 

Keywords :   


Allied-Bristol Life Sciences Launches ieCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway

2016-03-30 07:03:23| drugdiscoveryonline Home Page

Allied-Bristol Life Sciences, LLC (ABLS), a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company, announced that it has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway

Tags: the life school develop

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.06Farm Progress America, June 18, 2024
18.06Farm Progress America, June 18, 2024
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Forecast Discussion Number 3
18.06Potential Tropical Cyclone One Wind Speed Probabilities Number 3
18.06Potential Tropical Cyclone One Public Advisory Number 3
18.06Summary for Potential Tropical Cyclone One (AT1/AL012024)
18.06Potential Tropical Cyclone One Forecast Advisory Number 3
More »